Bedrijfsoverzicht
EDAP TMS S.A. is a specialized enterprise focused on the development, manufacturing, promotion, and distribution of minimally-invasive medical devices specifically designed for urology, leveraging proprietary ultrasound technology across markets in Asia, France, the United States, and internationally. The company operates within the Healthcare sector, specifically targeting the Medical Distribution industry, which implies a business model reliant on the supply chain and logistics of specialized medical equipment rather than direct patient care or drug manufacturing. As of the latest available data, the company holds a market capitalization of $123.69M and reports an annual revenue of $70.53M, though the specific employee count is not disclosed in the provided records. These valuation and revenue figures position the company as a mid-cap entity with a significant operational footprint, suggesting it has established a substantial presence in the global urology device market despite facing recent challenges in revenue expansion.
Financiële gezondheid
The company's financial performance over the trailing twelve months reflects a challenging operational period, with total revenue standing at $70.53M, net income at -$29,246,000, and EBITDA at -$21,288,000. The substantial gap between the positive revenue of $70.53M and the negative net income of -$29,246,000 reveals a cost structure where operating expenses and taxes significantly erode the bottom line, indicating high burn rates or elevated overhead costs relative to sales volume. Free cash flow for the period is reported at -$12,130,500, which indicates a lack of immediate financial flexibility as the company is currently consuming cash reserves to fund its operations and strategic initiatives rather than generating surplus liquidity. Margins further illustrate this pressure, with a gross margin of 42.5% showing that the core product sales retain a healthy portion of revenue after direct costs, but an operating margin of -26.2% and a profit margin of -41.5% demonstrate that overhead and other expenses are driving significant losses at the operational and net levels. On the balance sheet, the company holds $20.45M in cash against $27.75M in debt, resulting in a debt-to-equity ratio of 142.93, which characterizes a highly leveraged financial position where liabilities substantially exceed equity. Liquidity is supported by a current ratio of 1.54, suggesting the company maintains sufficient current assets to cover its short-term obligations, providing a buffer against immediate solvency risks. Return metrics highlight the severity of the losses, with a return on equity of -94.5% and a return on assets of -18.3%, revealing that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized to support asset growth.
Waarderingsbeoordeling
Valuation multiples for EDAP TMS S.A. present a complex picture due to the company's loss-making status, with a trailing P/E ratio of N/A and a forward P/E of -5.89. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a continuation of negative earnings, where future earnings expectations are not yet positive enough to support a traditional multiple. The price-to-book ratio stands at 6.37, indicating that the market values the company's equity at a significant premium of over six times its book value, which often suggests investors are betting on intangible assets or future recovery potential rather than current asset backing. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.75 and an EV/EBITDA of -6.15, suggesting that investors are valuing the company primarily on its revenue generation capabilities rather than profitability or earnings power. Price volatility is evident when observing the 52-week high of $5.05 and the 52-week low of $1.21, placing the current trading price within a wide range that reflects significant market uncertainty. The beta value of -0.08 is highly unusual for an equity security, suggesting an inverse correlation to the broader market or extreme volatility that defies standard market movements, further complicating the risk profile assessment.
Growth & Income
Revenue growth year-over-year has declined by -19.0%, while earnings growth is listed as N/A due to the negative earnings base, meaning earnings are contracting rather than expanding. This contraction in revenue directly impacts the ability to cover fixed costs, and since earnings are already negative, the lack of earnings growth indicates a deepening of losses rather than a recovery in profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash is being retained to fund operations and potentially reduce the high debt load rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a complete absence of income distribution, signaling a company in a turnaround phase that relies entirely on operational efficiency improvements to eventually restore profitability and consider capital allocation to shareholders.